Angelo Porciuncula
Associate Research Scientist
Research & Publications
Biography
Selected Publications
- Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancerPorciuncula A, Appleman V, Parent A, Raizer J, Gregory R, Lineberry N, Abu-Yousif A, Schalper K. Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer. Cancer Research 2024, 84: 6732-6732. DOI: 10.1158/1538-7445.am2024-6732.
- Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulationSchalper K, Matsuda A, Ganno-Sherwood M, Maldonado-Lopez A, Rosentrater E, Porciuncula A, Zhang D, Christensen C, Merrigan S, Hatten T, Lee H, Lee M, Dong L, Huang J, Iartchouk N, Wang J, Xu H, Yoneyama T, Piatkov K, Harbison C, Parent A, Lineberry N, Abu-Yousif A, Appleman V. Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation. Cancer Research 2023, 83: 1841-1841. DOI: 10.1158/1538-7445.am2023-1841.